The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells Journal Article


Authors: Xu, W.; Yuan, X.; Jung, Y. J.; Yang, Y.; Basso, A.; Rosen, N.; Chung, E. J.; Trepel, J.; Neckers, L.
Article Title: The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells
Abstract: AKT, a serine/threonine kinase that promotes cell survival, can be activated by overexpression of the receptor tyrosine kinase ErbB2. Conversely, down-regulation of ErbB2 inhibits AKT activation. Here, we identify PP1 as a serine/threonine phosphatase that associates with and dephosphorylates AKT in breast cancer cells, and we show that ErbB2 inhibits PP1-dependent dephosphorylation of AKT. Inhibition of ErbB2 by either the HSP (heat shock protein) 90 inhibitor geldanamycin or the ErbB inhibitor ZD1839 in SKBR3 cells, a human breast cancer cell line overexpressing ErbB2 protein, induces a rapid and dramatic decrease in AKT activity. Decreased AKT activity occurs many hours before the HSP90-dependent decline of AKT protein but is correlated with loss of AKT phosphorylation. Decreased AKT phosphorylation is not due to blockade of AKT activation or to preferential HSP90-mediated degradation of phosphorylated AKT. Instead, it is caused by increased AKT dephosphorylation. Sensitivity to a panel of phosphatase inhibitors suggests involvement of the phosphatase PP1 in this process. In vitro phosphatase assay (using PP1 immunoprecipitated from COS7 cells transiently transfected with the wild-type protein, as well as purified PP1) confirmed that AKT is a substrate of PP1. Furthermore, endogenous PP1 and AKT associate with each other in SKBR3. However, the phosphatase is phosphorylated and its activity is suppressed (determined by in vitro assay). In contrast, ErbB2 inhibition abrogates PP1 phosphorylation and restores its activity (measured by its ability to dephosphorylate AKT in vitro). Finally, transient overexpression of constitutively active PP1 in SKBR3 cells promotes marked dephosphorylation of endogenous AKT protein. These data indicate that ErbB2 acts to preserve the phosphorylation, and hence to prolong the activation, of AKT kinase by repressing the activity of the phosphatase PP1. ErbB2 thus functions to regulate AKT kinase by simultaneously promoting its activation while inhibiting its inactivation.
Keywords: protein kinase b; controlled study; human cell; proto-oncogene proteins; animals; gene overexpression; protein degradation; enzyme activation; enzyme activity; cell line, tumor; breast neoplasms; cos cells; phosphorylation; enzyme inhibitors; protein-serine-threonine kinases; gene identification; cancer cell; breast carcinoma; proto-oncogene proteins c-akt; gefitinib; immunoprecipitation; heat shock protein 90; hsp90 heat-shock proteins; quinones; receptor, erbb-2; antibiotics, antineoplastic; quinazolines; drug sensitivity; benzoquinones; lactams, macrocyclic; phosphoprotein phosphatase; geldanamycin; dephosphorylation; humans; human; priority journal; article
Journal Title: Cancer Research
Volume: 63
Issue: 22
ISSN: 0008-5472
Publisher: American Association for Cancer Research  
Date Published: 2003-11-15
Start Page: 7777
End Page: 7784
Language: English
PUBMED: 14633703
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 12 September 2014 -- Source: Scopus
Citation Impact
MSK Authors
  1. Andrea D. Basso
    32 Basso
  2. Neal Rosen
    425 Rosen